Strategies and therapies for managing relapsed/refractory multiple myeloma (RRMM) have changed dramatically over the past few decades. With a growing number of choices and combinations, the clinician must carefully balance patient factors including age, performance status, and comorbidities; disease factors such as burden and biologic markers; and treatment factors such as previous lines of therapy, route of administration, and toxicity for each individual patient. In this interactive CE/CME activity, two illustrative case studies challenge learners to make appropriate clinical choices for disease control while minimizing toxicity and enhancing quality of life.
Case studies with interactive benchmarking
After completing this activity, participants should be better able to:
- Describe factors to consider in the evaluation and management of patients with suspected influenza
- Individualize flu treatment with available antiviral medication based on current evidence
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
Nurse Planner: Karen A. Pekle, MS, ANP-C, AOCN
AAPA Credit Designation
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until August 2, 2020. PAs should only claim credit commensurate with the extent of their participation.
PA Planner: Joel Andrews, PA-C
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from Celgene Corporation.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Chari: advisory board: Karyopharm, Oncopeptides, Sanofi Aventis, Seattle Genetics; advisory board/consultant: Amgen, Celgene, Janssen, Novartis; consultant: Bristol-Myers Squibb, Millennium/Takeda; grant/research support: Amgen, Celgene, Janssen, Novartis, Pharmacyclics, Seattle Genetics.
None of the members of the Planning Committee or CE Alliance staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the activity in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: August 2, 2019
Expiration date: August 2, 2020
© 2020 Practicing Clinicians Exchange. All Rights Reserved. CGPCE96219